vs
Indivior Pharmaceuticals, Inc.（INDV）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Indivior Pharmaceuticals, Inc.的季度营收约是Rocket Lab Corp的2.0倍（$357.0M vs $179.7M），Indivior Pharmaceuticals, Inc.净利率更高（28.9% vs -29.5%，领先58.3%），Rocket Lab Corp自由现金流更多（$-114.2M vs $-245.0M）
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
INDV vs RKLB — 直观对比
营收规模更大
INDV
是对方的2.0倍
$179.7M
净利率更高
INDV
高出58.3%
-29.5%
自由现金流更多
RKLB
多$130.8M
$-245.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $357.0M | $179.7M |
| 净利润 | $103.0M | $-52.9M |
| 毛利率 | 82.1% | 38.0% |
| 营业利润率 | 22.7% | -28.4% |
| 净利率 | 28.9% | -29.5% |
| 营收同比 | — | 35.7% |
| 净利润同比 | 390.5% | -1.1% |
| 每股收益（稀释后） | $0.79 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDVRKLB
| Q4 25 | $357.0M | $179.7M | ||
| Q3 25 | $314.0M | $155.1M | ||
| Q2 25 | $302.0M | $144.5M | ||
| Q1 25 | $266.0M | $122.6M | ||
| Q4 24 | — | $132.4M | ||
| Q3 24 | $307.0M | $104.8M | ||
| Q2 24 | $299.0M | $106.3M | ||
| Q1 24 | — | $92.8M |
净利润INDVRKLB
| Q4 25 | $103.0M | $-52.9M | ||
| Q3 25 | $42.0M | $-18.3M | ||
| Q2 25 | $18.0M | $-66.4M | ||
| Q1 25 | $47.0M | $-60.6M | ||
| Q4 24 | — | $-52.3M | ||
| Q3 24 | $22.0M | $-51.9M | ||
| Q2 24 | $-97.0M | $-41.6M | ||
| Q1 24 | — | $-44.3M |
毛利率INDVRKLB
| Q4 25 | 82.1% | 38.0% | ||
| Q3 25 | 73.2% | 37.0% | ||
| Q2 25 | 82.8% | 32.1% | ||
| Q1 25 | 83.1% | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | 78.5% | 26.7% | ||
| Q2 24 | 73.6% | 25.6% | ||
| Q1 24 | — | 26.1% |
营业利润率INDVRKLB
| Q4 25 | 22.7% | -28.4% | ||
| Q3 25 | 13.7% | -38.0% | ||
| Q2 25 | 23.8% | -41.3% | ||
| Q1 25 | 24.8% | -48.3% | ||
| Q4 24 | — | -38.9% | ||
| Q3 24 | 11.4% | -49.5% | ||
| Q2 24 | -39.5% | -40.7% | ||
| Q1 24 | — | -46.4% |
净利率INDVRKLB
| Q4 25 | 28.9% | -29.5% | ||
| Q3 25 | 13.4% | -11.8% | ||
| Q2 25 | 6.0% | -46.0% | ||
| Q1 25 | 17.7% | -49.5% | ||
| Q4 24 | — | -39.5% | ||
| Q3 24 | 7.2% | -49.6% | ||
| Q2 24 | -32.4% | -39.2% | ||
| Q1 24 | — | -47.7% |
每股收益（稀释后）INDVRKLB
| Q4 25 | $0.79 | $-0.09 | ||
| Q3 25 | $0.33 | $-0.03 | ||
| Q2 25 | $0.14 | $-0.13 | ||
| Q1 25 | $0.38 | $-0.12 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | $0.16 | $-0.10 | ||
| Q2 24 | $-0.72 | $-0.08 | ||
| Q1 24 | — | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.0M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $-98.0M | $1.7B |
| 总资产 | $1.2B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
现金及短期投资INDVRKLB
| Q4 25 | $195.0M | $1.0B | ||
| Q3 25 | $445.0M | $976.7M | ||
| Q2 25 | $510.0M | $688.1M | ||
| Q1 25 | $373.0M | $428.4M | ||
| Q4 24 | — | $419.0M | ||
| Q3 24 | — | $442.4M | ||
| Q2 24 | — | $496.8M | ||
| Q1 24 | — | $492.5M |
总债务INDVRKLB
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
股东权益INDVRKLB
| Q4 25 | $-98.0M | $1.7B | ||
| Q3 25 | $-207.0M | $1.3B | ||
| Q2 25 | $-257.0M | $688.5M | ||
| Q1 25 | $-285.0M | $431.3M | ||
| Q4 24 | — | $382.5M | ||
| Q3 24 | $-310.0M | $419.8M | ||
| Q2 24 | $-281.0M | $455.2M | ||
| Q1 24 | — | $478.9M |
总资产INDVRKLB
| Q4 25 | $1.2B | $2.3B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
负债/权益比INDVRKLB
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-221.0M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $-245.0M | $-114.2M |
| 自由现金流率自由现金流/营收 | -68.6% | -63.6% |
| 资本支出强度资本支出/营收 | 6.7% | 27.6% |
| 现金转化率经营现金流/净利润 | -2.15× | — |
| 过去12个月自由现金流最近4个季度 | $-93.0M | $-321.8M |
8季度趋势，按日历期对齐
经营现金流INDVRKLB
| Q4 25 | $-221.0M | $-64.5M | ||
| Q3 25 | $-39.0M | $-23.5M | ||
| Q2 25 | $158.0M | $-23.2M | ||
| Q1 25 | $75.0M | $-54.2M | ||
| Q4 24 | — | $-2.4M | ||
| Q3 24 | $2.0M | $-30.9M | ||
| Q2 24 | $88.0M | $-13.0M | ||
| Q1 24 | — | $-2.6M |
自由现金流INDVRKLB
| Q4 25 | $-245.0M | $-114.2M | ||
| Q3 25 | $-59.0M | $-69.4M | ||
| Q2 25 | $141.0M | $-55.3M | ||
| Q1 25 | $70.0M | $-82.9M | ||
| Q4 24 | — | $-23.9M | ||
| Q3 24 | $-5.0M | $-41.9M | ||
| Q2 24 | $84.0M | $-28.3M | ||
| Q1 24 | — | $-21.8M |
自由现金流率INDVRKLB
| Q4 25 | -68.6% | -63.6% | ||
| Q3 25 | -18.8% | -44.8% | ||
| Q2 25 | 46.7% | -38.3% | ||
| Q1 25 | 26.3% | -67.6% | ||
| Q4 24 | — | -18.1% | ||
| Q3 24 | -1.6% | -40.0% | ||
| Q2 24 | 28.1% | -26.7% | ||
| Q1 24 | — | -23.5% |
资本支出强度INDVRKLB
| Q4 25 | 6.7% | 27.6% | ||
| Q3 25 | 6.4% | 29.6% | ||
| Q2 25 | 5.6% | 22.2% | ||
| Q1 25 | 1.9% | 23.4% | ||
| Q4 24 | — | 16.3% | ||
| Q3 24 | 2.3% | 10.5% | ||
| Q2 24 | 1.3% | 14.4% | ||
| Q1 24 | — | 20.7% |
现金转化率INDVRKLB
| Q4 25 | -2.15× | — | ||
| Q3 25 | -0.93× | — | ||
| Q2 25 | 8.78× | — | ||
| Q1 25 | 1.60× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
